Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the brand-name medicine, including clinically isolated syndrome, relapsing-remitting MS (RRMS), […]
The post New Tysabri biosimilar Tyruko now on market for relapsing MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com